Abstract
Gonadotrophin receptor hormone analogues (GnRHa) have been used in a range of sex hormone-dependent disorders. In the management of premenstrual syndrome, they can completely abolish symptoms. The success of GnRHa in the treatment of endometriosis and adjuvant therapy in the management of fibroids is proven. This efficacy does not come without a cost and the side-effects of the hypo-estrogenic state have limited their application. The use of add-back therapy to counter these effects has enabled wider application, longer durations of treatment and an increase in compliance. This review article is an update on the evidence supporting gonadotrophin receptor hormone analogues in combination with add-back therapy.
MeSH terms
-
Bone Density / drug effects
-
Bone Density Conservation Agents / therapeutic use
-
Calcitonin / therapeutic use
-
Diphosphonates / therapeutic use
-
Endometriosis / drug therapy
-
Estrogen Antagonists / therapeutic use
-
Estrogen Receptor Modulators / therapeutic use
-
Female
-
Gonadotropin-Releasing Hormone / analogs & derivatives*
-
Gonadotropin-Releasing Hormone / pharmacology
-
Gonadotropin-Releasing Hormone / therapeutic use*
-
Hormone Replacement Therapy
-
Humans
-
Leiomyoma / drug therapy
-
Lipids / blood
-
Menstruation Disturbances / drug therapy
-
Norpregnenes / therapeutic use
-
Parathyroid Hormone / therapeutic use
-
Premenstrual Syndrome / drug therapy*
-
Raloxifene Hydrochloride / therapeutic use
-
Uterine Diseases / drug therapy
-
Vitamin D / therapeutic use
Substances
-
Bone Density Conservation Agents
-
Diphosphonates
-
Estrogen Antagonists
-
Estrogen Receptor Modulators
-
Lipids
-
Norpregnenes
-
Parathyroid Hormone
-
Vitamin D
-
Gonadotropin-Releasing Hormone
-
Raloxifene Hydrochloride
-
Calcitonin
-
tibolone